Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92

L. Caputi, A. H. Hainsworth, F. Lavaroni, M. J. Leach, N. C L McNaughton, N. B. Mercuri, A. D. Randall, F. Spadoni, J. H. Swan, A. Stefani

Research output: Contribution to journalArticle

Abstract

202W92 (R-(-)-2,4-diamino-6-(fluromethyl)-5-(2,3,5-trichlorophenyl) pyrimidine) is a novel compound in the same chemical series as the antiepileptic drug lamotrigine and the neuroprotective sipatrigine. Here 202W92 was quantitatively assessed as a neuroprotective agent in focal cerebral ischaemia, and as an inhibitor of sodium and calcium channels and of synaptic transmission. In the rat permanent middle cerebral artery occlusion (MCAO) model of acute focal ischaemia, 202W92 reduced infarct volume by 75% in cortex and by 80% in basal ganglia, with ED 50 approximately 2 mg/kg (single i.v. dose, 10 min post-occlusion). In whole-cell current recordings from single cells, 202W92 completely and reversibly inhibited voltage gated sodium channels (IC 50 3×10 -6 M) in rat freshly-isolated cortical neurons and in the GH 3 pituitary cell line. 202W92 also inhibited a nifedipine-sensitive fraction (approximately 35%) of native high-voltage-activated (HVA) calcium current in rat cortical neurons (IC 50 15×10 -6 M) and weakly inhibited low-voltage-activated (LVA) calcium currents of the recombinant α1I-mediated T-type (IC 50>100×10 -6 M). The drug inhibited the amplitude and frequency of 4-aminopyridine-evoked glutamatergic excitatory post-synaptic currents (EPSCs). In conclusion, 202W92 is an effective neuroprotective agent when administered post-ischaemia and a potent sodium channel inhibitor in vitro.

Original languageEnglish
Pages (from-to)259-268
Number of pages10
JournalBrain Research
Volume919
Issue number2
DOIs
Publication statusPublished - Nov 23 2001

Fingerprint

Neuroprotective Agents
Ischemia
Sodium Channel Blockers
Voltage-Gated Sodium Channels
Calcium
Neurons
4-Aminopyridine
Sodium Channels
Middle Cerebral Artery Infarction
Patch-Clamp Techniques
Calcium Channels
Nifedipine
Basal Ganglia
Brain Ischemia
Synaptic Transmission
Anticonvulsants
Cell Line
Pharmaceutical Preparations
In Vitro Techniques
sipatrigine

Keywords

  • 202W92
  • Brain ischemia
  • Neuroprotective
  • Sodium channel pharmacology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Caputi, L., Hainsworth, A. H., Lavaroni, F., Leach, M. J., McNaughton, N. C. L., Mercuri, N. B., ... Stefani, A. (2001). Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. Brain Research, 919(2), 259-268. https://doi.org/10.1016/S0006-8993(01)03029-3

Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. / Caputi, L.; Hainsworth, A. H.; Lavaroni, F.; Leach, M. J.; McNaughton, N. C L; Mercuri, N. B.; Randall, A. D.; Spadoni, F.; Swan, J. H.; Stefani, A.

In: Brain Research, Vol. 919, No. 2, 23.11.2001, p. 259-268.

Research output: Contribution to journalArticle

Caputi, L, Hainsworth, AH, Lavaroni, F, Leach, MJ, McNaughton, NCL, Mercuri, NB, Randall, AD, Spadoni, F, Swan, JH & Stefani, A 2001, 'Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92', Brain Research, vol. 919, no. 2, pp. 259-268. https://doi.org/10.1016/S0006-8993(01)03029-3
Caputi, L. ; Hainsworth, A. H. ; Lavaroni, F. ; Leach, M. J. ; McNaughton, N. C L ; Mercuri, N. B. ; Randall, A. D. ; Spadoni, F. ; Swan, J. H. ; Stefani, A. / Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. In: Brain Research. 2001 ; Vol. 919, No. 2. pp. 259-268.
@article{d88d50bc2b794b0594de36700e7ae3c4,
title = "Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92",
abstract = "202W92 (R-(-)-2,4-diamino-6-(fluromethyl)-5-(2,3,5-trichlorophenyl) pyrimidine) is a novel compound in the same chemical series as the antiepileptic drug lamotrigine and the neuroprotective sipatrigine. Here 202W92 was quantitatively assessed as a neuroprotective agent in focal cerebral ischaemia, and as an inhibitor of sodium and calcium channels and of synaptic transmission. In the rat permanent middle cerebral artery occlusion (MCAO) model of acute focal ischaemia, 202W92 reduced infarct volume by 75{\%} in cortex and by 80{\%} in basal ganglia, with ED 50 approximately 2 mg/kg (single i.v. dose, 10 min post-occlusion). In whole-cell current recordings from single cells, 202W92 completely and reversibly inhibited voltage gated sodium channels (IC 50 3×10 -6 M) in rat freshly-isolated cortical neurons and in the GH 3 pituitary cell line. 202W92 also inhibited a nifedipine-sensitive fraction (approximately 35{\%}) of native high-voltage-activated (HVA) calcium current in rat cortical neurons (IC 50 15×10 -6 M) and weakly inhibited low-voltage-activated (LVA) calcium currents of the recombinant α1I-mediated T-type (IC 50>100×10 -6 M). The drug inhibited the amplitude and frequency of 4-aminopyridine-evoked glutamatergic excitatory post-synaptic currents (EPSCs). In conclusion, 202W92 is an effective neuroprotective agent when administered post-ischaemia and a potent sodium channel inhibitor in vitro.",
keywords = "202W92, Brain ischemia, Neuroprotective, Sodium channel pharmacology",
author = "L. Caputi and Hainsworth, {A. H.} and F. Lavaroni and Leach, {M. J.} and McNaughton, {N. C L} and Mercuri, {N. B.} and Randall, {A. D.} and F. Spadoni and Swan, {J. H.} and A. Stefani",
year = "2001",
month = "11",
day = "23",
doi = "10.1016/S0006-8993(01)03029-3",
language = "English",
volume = "919",
pages = "259--268",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92

AU - Caputi, L.

AU - Hainsworth, A. H.

AU - Lavaroni, F.

AU - Leach, M. J.

AU - McNaughton, N. C L

AU - Mercuri, N. B.

AU - Randall, A. D.

AU - Spadoni, F.

AU - Swan, J. H.

AU - Stefani, A.

PY - 2001/11/23

Y1 - 2001/11/23

N2 - 202W92 (R-(-)-2,4-diamino-6-(fluromethyl)-5-(2,3,5-trichlorophenyl) pyrimidine) is a novel compound in the same chemical series as the antiepileptic drug lamotrigine and the neuroprotective sipatrigine. Here 202W92 was quantitatively assessed as a neuroprotective agent in focal cerebral ischaemia, and as an inhibitor of sodium and calcium channels and of synaptic transmission. In the rat permanent middle cerebral artery occlusion (MCAO) model of acute focal ischaemia, 202W92 reduced infarct volume by 75% in cortex and by 80% in basal ganglia, with ED 50 approximately 2 mg/kg (single i.v. dose, 10 min post-occlusion). In whole-cell current recordings from single cells, 202W92 completely and reversibly inhibited voltage gated sodium channels (IC 50 3×10 -6 M) in rat freshly-isolated cortical neurons and in the GH 3 pituitary cell line. 202W92 also inhibited a nifedipine-sensitive fraction (approximately 35%) of native high-voltage-activated (HVA) calcium current in rat cortical neurons (IC 50 15×10 -6 M) and weakly inhibited low-voltage-activated (LVA) calcium currents of the recombinant α1I-mediated T-type (IC 50>100×10 -6 M). The drug inhibited the amplitude and frequency of 4-aminopyridine-evoked glutamatergic excitatory post-synaptic currents (EPSCs). In conclusion, 202W92 is an effective neuroprotective agent when administered post-ischaemia and a potent sodium channel inhibitor in vitro.

AB - 202W92 (R-(-)-2,4-diamino-6-(fluromethyl)-5-(2,3,5-trichlorophenyl) pyrimidine) is a novel compound in the same chemical series as the antiepileptic drug lamotrigine and the neuroprotective sipatrigine. Here 202W92 was quantitatively assessed as a neuroprotective agent in focal cerebral ischaemia, and as an inhibitor of sodium and calcium channels and of synaptic transmission. In the rat permanent middle cerebral artery occlusion (MCAO) model of acute focal ischaemia, 202W92 reduced infarct volume by 75% in cortex and by 80% in basal ganglia, with ED 50 approximately 2 mg/kg (single i.v. dose, 10 min post-occlusion). In whole-cell current recordings from single cells, 202W92 completely and reversibly inhibited voltage gated sodium channels (IC 50 3×10 -6 M) in rat freshly-isolated cortical neurons and in the GH 3 pituitary cell line. 202W92 also inhibited a nifedipine-sensitive fraction (approximately 35%) of native high-voltage-activated (HVA) calcium current in rat cortical neurons (IC 50 15×10 -6 M) and weakly inhibited low-voltage-activated (LVA) calcium currents of the recombinant α1I-mediated T-type (IC 50>100×10 -6 M). The drug inhibited the amplitude and frequency of 4-aminopyridine-evoked glutamatergic excitatory post-synaptic currents (EPSCs). In conclusion, 202W92 is an effective neuroprotective agent when administered post-ischaemia and a potent sodium channel inhibitor in vitro.

KW - 202W92

KW - Brain ischemia

KW - Neuroprotective

KW - Sodium channel pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0035940739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035940739&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(01)03029-3

DO - 10.1016/S0006-8993(01)03029-3

M3 - Article

C2 - 11701138

AN - SCOPUS:0035940739

VL - 919

SP - 259

EP - 268

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -